Relative Bioavailability of ESK-001 Tablet Versus Liquid in Healthy Participants

Completed · Phase 1

Conditions studied: Pharmacokinetics

In brief

This is a single-center, in-house, open-label, crossover study in 15 healthy participants.

Key facts

Study ID

NCT05330858

Run by

Alumis Inc

People needed

14

Starts

2022-03-17

Expected to finish

2022-09-20

Last updated by the study team

2023-05-09

Who can join

Age: 18 and older, up to 60. Sex: any. Healthy volunteers: accepted.

You may qualify if…

• Healthy Men and woman age 18-60
• Able to provide written informed consent
• Females can not be pregnant or lactating

You may not qualify if…

• Prior exposure to ESK-001
• History of malignancy within the last 10 years
• Positive for HIV, Hepatitis B or C
• History of tuberculosis
• Positive test for alcohol or drugs

Where it is running

• Alumis Central Site — Glendale, California, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.